{"product_id":"rmd-marketing-mix","title":"ResMed Inc. (RMD): Marketing Mix Analysis [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Marketing Mix Analysis of ResMed Inc. gives you a clear, research-based view of how the business is positioned in late 2025 across product, place, promotion, and price, with focus on the AirSense 11 PAP platform, AirTouch F30i Comfort mask, myAir, AirView, and the Smart Comfort FDA clearance in December 2025. You’ll see how ResMed reaches customers in \u003cstrong\u003e140\u003c\/strong\u003e countries through durable-medical-equipment channels, uses clinical evidence and launch signals such as the Lancet-linked \u003cstrong\u003e77M\u003c\/strong\u003e U.S. sleep apnea cases, and supports monetization through devices, masks, software, and consumables, alongside FY2025 R\u0026amp;D spend of \u003cstrong\u003e$400M\u003c\/strong\u003e, gross margin of \u003cstrong\u003e59.2%\u003c\/strong\u003e, and a FY2026 guide of \u003cstrong\u003e62%\u003c\/strong\u003e to \u003cstrong\u003e63%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - Marketing Mix: Product\u003c\/h2\u003e\n\u003cp\u003eResMed Inc. reported \u003cstrong\u003e$400 million\u003c\/strong\u003e in research and development spending in FY2025. The company’s product mix centers on connected sleep and respiratory care hardware, software, and data services that are built around long-term device use and recurring digital engagement.\u003c\/p\u003e\n\n\u003cp\u003eThe core product platform is \u003cstrong\u003eAirSense 11\u003c\/strong\u003e, a positive airway pressure, or PAP, device line used for sleep apnea therapy. It is part of a connected care stack rather than a standalone machine, because the device is designed to work with masks, mobile coaching, and cloud-based monitoring. For you, this matters because the product is not only the device itself; it is the full treatment system around adherence, tracking, and clinician oversight.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eProduct element\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eResMed Inc. offering\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eBusiness role\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePAP device\u003c\/td\u003e\n    \u003ctd\u003eAirSense 11\u003c\/td\u003e\n    \u003ctd\u003eCore therapy hardware for sleep apnea treatment\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMask\u003c\/td\u003e\n    \u003ctd\u003eAirTouch F30i\u003c\/td\u003e\n    \u003ctd\u003ePatient comfort interface between device and therapy user\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDigital ecosystem\u003c\/td\u003e\n    \u003ctd\u003emyAir and AirView\u003c\/td\u003e\n    \u003ctd\u003ePatient engagement and clinician monitoring\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInnovation input\u003c\/td\u003e\n    \u003ctd\u003eFY2025 R\u0026amp;D spend: \u003cstrong\u003e$400 million\u003c\/strong\u003e\n\u003c\/td\u003e\n    \u003ctd\u003eSupports product development, software, and device improvement\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAirSense 11\u003c\/strong\u003e is the anchor product because PAP therapy depends on both device performance and user compliance. In practical terms, the device has to be comfortable, quiet, easy to set up, and connected enough to support long-term use. That makes product design a retention issue as much as a medical-device issue. If a patient stops using therapy, the value of the product falls quickly.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAirTouch F30i\u003c\/strong\u003e is part of the same product system. Masks are important because they affect seal quality, comfort, and adherence. A mask that is easier to wear can improve nightly use, which supports both clinical outcomes and customer retention. In a marketing mix analysis, this means the mask is not a separate add-on; it is a companion product that strengthens the main device proposition.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDevice\u003c\/strong\u003e: AirSense 11 supports PAP therapy delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMask\u003c\/strong\u003e: AirTouch F30i supports fit and comfort.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSoftware\u003c\/strong\u003e: myAir supports patient engagement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClinician tools\u003c\/strong\u003e: AirView supports remote monitoring and workflow.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eR\u0026amp;D\u003c\/strong\u003e: \u003cstrong\u003e$400 million\u003c\/strong\u003e in FY2025 supports product iteration and connected features.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe \u003cstrong\u003emyAir\u003c\/strong\u003e and \u003cstrong\u003eAirView\u003c\/strong\u003e cloud ecosystem turns the product into a connected service model. myAir is the patient-facing layer, while AirView is the clinician-facing layer. This split matters because it creates two value streams: direct patient support and professional monitoring. It also makes the product harder to replace, since users and providers can become embedded in the same data environment.\u003c\/p\u003e\n\n\u003cp\u003eResMed Inc.’s product strategy depends on a combined hardware-plus-software model. The device drives therapy, the mask drives comfort, and the digital platform drives monitoring and follow-up. That combination is a strong product-market fit in sleep apnea care because the condition requires nightly use and ongoing adherence support.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eProduct layer\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eCustomer\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eValue delivered\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAirSense 11\u003c\/td\u003e\n    \u003ctd\u003ePatient and provider\u003c\/td\u003e\n    \u003ctd\u003eTherapy delivery\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAirTouch F30i\u003c\/td\u003e\n    \u003ctd\u003ePatient\u003c\/td\u003e\n    \u003ctd\u003eFit and comfort\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003emyAir\u003c\/td\u003e\n    \u003ctd\u003ePatient\u003c\/td\u003e\n    \u003ctd\u003eAdherence support and usage feedback\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAirView\u003c\/td\u003e\n    \u003ctd\u003eClinician\u003c\/td\u003e\n    \u003ctd\u003eRemote monitoring and care management\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eFY2025 R\u0026amp;D spend: $400 million\u003c\/strong\u003e signals that product development is a major cost center and strategic priority. In business analysis, research and development spending shows how much a company invests in future product quality, software, device upgrades, and new therapeutic features. For ResMed Inc., that spending supports both incremental product improvements and the connected platform that links device, patient, and provider.\u003c\/p\u003e\n\n\u003cp\u003eThe product mix is also built for recurring use rather than one-time purchase behavior. A PAP device and mask require replacement, maintenance, and ongoing software interaction. That creates a product structure with repeat demand, which is important in an industry where adherence and service quality drive long-term revenue potential.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eAirSense 11 anchors the product portfolio.\u003c\/li\u003e\n  \u003cli\u003eAirTouch F30i strengthens comfort and fit.\u003c\/li\u003e\n  \u003cli\u003emyAir increases patient interaction with therapy.\u003c\/li\u003e\n \u003cli\u003eAirView extends product value to healthcare providers.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e$400 million\u003c\/strong\u003e in FY2025 R\u0026amp;D supports continuous product development.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - Marketing Mix: Place\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e140 countries\u003c\/strong\u003e is the clearest sign of ResMed Inc.’s distribution reach. The company’s Place strategy is built around global availability, with a heavy dependence on the durable medical equipment channel, home-care providers, and connected-care distribution pathways.\u003c\/p\u003e\n\n\u003cp\u003eResMed Inc. sells in \u003cstrong\u003e140 countries\u003c\/strong\u003e, which means Place is not a single-country retail model. It is a multi-country supply network that has to move devices, masks, and software-enabled services through local regulatory and reimbursement systems, especially in sleep apnea and respiratory care markets.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003ePlace factor\u003c\/th\u003e\n    \u003cth\u003eReal-life data\u003c\/th\u003e\n    \u003cth\u003eDistribution meaning\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCountry reach\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e140 countries\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eWide international availability across multiple healthcare systems\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eWorkforce scale\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e10,000+\u003c\/strong\u003e global workforce\u003c\/td\u003e\n    \u003ctd\u003eSupports regional sales, regulatory, logistics, and customer service coverage\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eChannel structure\u003c\/td\u003e\n    \u003ctd\u003eDurable medical equipment channel focus\u003c\/td\u003e\n    \u003ctd\u003eProducts move through clinical and home-care distribution rather than mass retail\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct access model\u003c\/td\u003e\n    \u003ctd\u003eCloud-connected device footprint\u003c\/td\u003e\n    \u003ctd\u003eDevice placement supports ongoing data transfer, patient follow-up, and provider monitoring\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eLaunch pattern\u003c\/td\u003e\n    \u003ctd\u003eU.S. launch followed Australia and Canada\u003c\/td\u003e\n    \u003ctd\u003eMarket entry can be sequenced across countries based on regulatory and channel readiness\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe durable medical equipment channel is central because it places ResMed Inc. products into the part of healthcare where prescription fulfillment, insurance processing, and patient onboarding happen. In practical terms, this means the company does not rely mainly on direct consumer retail shelves. Instead, access depends on relationships with DME providers, sleep clinics, payers, and home medical suppliers.\u003c\/p\u003e\n\n\u003cp\u003eThe U.S. launch pattern following Australia and Canada shows a staged Place strategy. That matters because medical-device distribution often depends on local approvals, reimbursement rules, and provider networks. A sequenced rollout reduces execution risk and lets ResMed Inc. adapt inventory, training, and service support market by market.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e140 countries\u003c\/strong\u003e creates scale, but also requires country-level logistics and compliance.\u003c\/li\u003e\n  \u003cli\u003eDurable medical equipment channels make access dependent on healthcare intermediaries, not just end-user demand.\u003c\/li\u003e\n  \u003cli\u003eCloud-connected devices improve placement efficiency because they stay linked to care workflows after delivery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e10,000+\u003c\/strong\u003e employees support regional coverage, service, and distribution operations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResMed Inc.’s global cloud-connected device footprint is important for Place because distribution does not end at shipment. Once a device is placed with a patient, the connection can continue through data transmission, monitoring, and follow-up care. That creates a distribution model that combines physical delivery with digital continuity.\u003c\/p\u003e\n\n\u003cp\u003eThe company’s \u003cstrong\u003e10,000+\u003c\/strong\u003e global workforce also matters for Place because wide geographic reach needs people in sales, supply chain, logistics, technical support, and clinical education. A network spread across \u003cstrong\u003e140 countries\u003c\/strong\u003e cannot run on shipping alone; it needs localized execution.\u003c\/p\u003e\n\n\u003cp\u003eFor academic work, the most useful Place angle is that ResMed Inc. uses a healthcare distribution model rather than a consumer-electronics model. Its access depends on \u003cstrong\u003e140 countries\u003c\/strong\u003e, DME channel relationships, cloud-connected devices, and a \u003cstrong\u003e10,000+\u003c\/strong\u003e employee support base.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - Marketing Mix: Promotion\u003c\/h2\u003e\n\u003cp\u003eResMed Inc. uses promotion to turn clinical legitimacy into consumer and provider demand. The core message is tied to medical evidence, FDA clearance, and patient adherence data, not broad consumer advertising.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e77 million\u003c\/strong\u003e U.S. adults were highlighted in a Lancet study as having sleep apnea, which gives ResMed a large addressable audience and a strong public-health message for promotion.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003ePromotion lever\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eReal-life fact\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003ePromotion effect\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFDA clearance\u003c\/td\u003e\n    \u003ctd\u003eFDA 510(k) clearance is used as a launch signal for medical devices\u003c\/td\u003e\n    \u003ctd\u003eSignals safety and regulatory acceptance, which matters for physicians, payers, and durable medical equipment channels\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical evidence\u003c\/td\u003e\n    \u003ctd\u003eThe Lancet study highlighted \u003cstrong\u003e77 million\u003c\/strong\u003e U.S. sleep apnea cases\u003c\/td\u003e\n    \u003ctd\u003eExpands awareness of untreated disease and supports diagnosis-driven demand\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePatient engagement\u003c\/td\u003e\n    \u003ctd\u003emyAir supports patients after purchase; AirView supports clinicians and care teams\u003c\/td\u003e\n    \u003ctd\u003eStrengthens adherence, follow-up, and replacement-cycle demand\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eProduct launches\u003c\/td\u003e\n    \u003ctd\u003eNew device and mask launches are part of ResMed’s market visibility strategy\u003c\/td\u003e\n    \u003ctd\u003eKeeps the brand visible in respiratory care and sleep medicine channels\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFDA clearance is central to promotion because it acts like a permission slip for market entry in a regulated category. For a device company, clearance does more than allow sales. It gives physicians, sleep labs, and distributors a clear signal that the product has passed a formal review process. That matters because medical buyers care about risk, evidence, and workflow fit before they care about branding.\u003c\/p\u003e\n\n\u003cp\u003eThe Lancet study referencing \u003cstrong\u003e77 million\u003c\/strong\u003e U.S. sleep apnea cases supports a problem-first promotion strategy. ResMed does not need to sell a lifestyle product; it can promote a clinical need. That shifts the message from preference to diagnosis, treatment, and long-term therapy. In academic work, this is a strong example of evidence-based positioning, where scientific data supports demand creation.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eFDA clearance supports launch credibility in regulated markets\u003c\/li\u003e\n  \u003cli\u003eClinical prevalence data supports awareness and screening\u003c\/li\u003e\n  \u003cli\u003eProvider trust matters more than mass-market advertising\u003c\/li\u003e\n  \u003cli\u003ePromotion is tied to diagnosis, adherence, and replacement demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eClinical evidence-led brand positioning helps ResMed speak to both professionals and patients. For doctors, the message is about validated treatment options, patient compliance, and workflow integration. For patients, the message is about easier therapy use and better daily follow-through. This matters because sleep apnea therapy often fails when patients stop using equipment, so promotion has to support both adoption and continued use.\u003c\/p\u003e\n\n\u003cp\u003emyAir and AirView reinforce promotion by extending the message after the sale. myAir is a patient-facing digital tool that supports engagement, while AirView is used by clinicians to monitor therapy and manage care. That makes promotion more than advertising. It becomes part of the treatment journey, because the digital layer helps keep users connected to the product and the care team.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\u003cstrong\u003eDigital tool\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003eUser group\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003ePromotional role\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003emyAir\u003c\/td\u003e\n    \u003ctd\u003ePatients\u003c\/td\u003e\n    \u003ctd\u003eSupports use, follow-up, and daily engagement\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eAirView\u003c\/td\u003e\n    \u003ctd\u003eClinicians and care teams\u003c\/td\u003e\n    \u003ctd\u003eSupports therapy review, patient management, and continuity of care\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eProduct launches support market visibility by keeping ResMed in professional conversations and device comparisons. In this category, launch activity matters because hospitals, sleep centers, and home-care providers often review new devices against existing treatment workflows. A launch is not just a product event. It is a promotional signal that the company is active, technically current, and still competing for attention in a medically sensitive market.\u003c\/p\u003e\n\n\u003cp\u003eResMed’s promotion mix is strongest when it combines regulatory credibility, disease awareness, and digital follow-through. That combination is more effective than price-led promotion in a category where patients often depend on physician recommendation and ongoing support.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eResMed Inc. - Marketing Mix: Price\u003c\/h2\u003e\n\n\u003cp\u003eResMed Inc. does not disclose public list prices here, so its pricing position is best read through \u003cstrong\u003eFY2025 gross margin of 59.2%\u003c\/strong\u003e and the \u003cstrong\u003eFY2026 gross margin guide of 62% to 63%\u003c\/strong\u003e. That margin profile shows a premium pricing structure supported by product performance, reimbursement access, and recurring consumable demand.\u003c\/p\u003e\n\n\u003cp\u003eThe company’s FY2025 revenue mix was \u003cstrong\u003e51% devices\u003c\/strong\u003e, \u003cstrong\u003e37% masks and other\u003c\/strong\u003e, and \u003cstrong\u003e12% RCS\u003c\/strong\u003e. This mix matters because it shows that pricing is not only tied to the upfront device sale. A large share of revenue comes from masks, other consumables, and software-linked services, which supports repeat billing and steadier realized pricing over time.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFY2025 gross margin\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e59.2%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eFY2026 gross margin guide\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e62% to 63%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRevenue mix - devices\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e51%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRevenue mix - masks and other\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e37%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRevenue mix - RCS\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe absence of public list prices gives ResMed Inc. flexibility in pricing by channel, geography, payer mix, and product category. In medical devices, that usually means the net price is shaped by reimbursement rates, contracts with distributors, hospital purchasing, and insurance coverage rather than a single shelf price. For academic analysis, this is important because the company’s pricing power is better measured by gross margin and mix than by a posted catalog price.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e59.2%\u003c\/strong\u003e gross margin in FY2025 is high enough to indicate meaningful pricing power and manufacturing discipline. The move to a \u003cstrong\u003e62% to 63%\u003c\/strong\u003e gross margin guide for FY2026 implies either stronger realized pricing, better mix, lower input costs, or a combination of all three. In pricing terms, that suggests the company can protect value even in a market where customers and payers are sensitive to cost.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDevices at 51%\u003c\/strong\u003e of revenue usually carry a more visible upfront price decision.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMasks and other at 37%\u003c\/strong\u003e support repeat purchases and recurring revenue.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRCS at 12%\u003c\/strong\u003e adds a software and services layer that can improve monetization beyond hardware sales.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe \u003cstrong\u003e37%\u003c\/strong\u003e share from masks and other is especially important for price strategy. Consumables are typically replaced more often than devices, so they create repeated transaction opportunities. That makes the effective lifetime value of a customer higher than the initial device sale alone. In plain English, the company can earn more across the life of one patient relationship than the first invoice suggests.\u003c\/p\u003e\n\n\u003cp\u003eRecurring software and consumables support monetization because they reduce dependence on one-time device pricing. RCS at \u003cstrong\u003e12%\u003c\/strong\u003e shows that a smaller but meaningful part of revenue comes from a service and software layer. For pricing, this matters because recurring revenue can smooth revenue timing and give the company more room to defend device pricing without relying only on volume growth.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003ctd\u003ePrice-related factor\u003c\/td\u003e\n    \u003ctd\u003eReal-life data point\u003c\/td\u003e\n    \u003ctd\u003ePricing implication\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGross margin\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e59.2%\u003c\/strong\u003e in FY2025\u003c\/td\u003e\n    \u003ctd\u003eIndicates strong realized pricing and cost control\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eGross margin outlook\u003c\/td\u003e\n    \u003ctd\u003e\n\u003cstrong\u003e62% to 63%\u003c\/strong\u003e in FY2026\u003c\/td\u003e\n    \u003ctd\u003eSignals further pricing or mix improvement\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eDevices revenue mix\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e51%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eUpfront hardware pricing remains central\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eMasks and other revenue mix\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e37%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eRecurring consumable pricing supports repeat sales\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRCS revenue mix\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e12%\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eSoftware and service pricing adds recurring monetization\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor a student paper, the cleanest way to frame ResMed Inc.’s price strategy is this: the company appears to use a value-based, mixed recurring-revenue model rather than a simple low-price strategy. The real evidence is the margin profile, the revenue mix, and the importance of consumables and software-linked revenue. Those numbers show that price is not just what customers pay once; it is what they pay across the full product cycle.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44602243514517,"sku":"rmd-marketing-mix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rmd-marketing-mix.png?v=1740210894","url":"https:\/\/dcf-model.com\/fr\/products\/rmd-marketing-mix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}